No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 18 of the 38 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:06:31.874Z. Latest historical point 2026-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T15:06:31.874Z. Latest historical point 2023-03-31.
The latest delayed quote for Entera Bio Ltd. (ENTX) stock was $2.60 as of Oct 6, 2026, 11:05 AM EDT, down 0.95% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +37.7% · 3-year avg +55.2%/yr · 5-year avg -10.6%/yr
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments.
Biotechnology · Jerusalem, JM
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.07
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.14
vs Estimate
$-0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ENTX | $127.91M | $2.60 | -0.95% | +37.68% | -10.57% | N/A | N/A |
| 2HCAT | $129.68M | $1.75 | -0.28% | -40.39% | -48.35% | N/A | vs ENTX |
| 3NRXP | $123.61M | $2.85 | -0.52% | -12.18% | -49.61% | N/A | vs ENTX |
| 4OGI | $132.79M | $0.94 | +0.67% | -49.99% | -36.62% | N/A | vs ENTX |
| 5FRNM | $133.37M | $16.35 | -2.85% | N/A | N/A | N/A | vs ENTX |
| 6ENGN | $122.26M | $1.82 | -2.41% | -75.71% | N/A | N/A | vs ENTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$9.75
+275.7% upside
Low
$9.00
Current
$2.60
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.07 | $-0.07 | 3 |
| Quarter ending Dec 2026 | $-0.15 | $-0.15 | $-0.15 | 3 |
| Quarter ending Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Quarter ending Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.42 | $-0.42 | $-0.42 | 3 |
| FY 2027 | $-0.38 | $-0.38 | $-0.38 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $54.58M | $54.58M | $54.58M | 3 |
| FY 2027 | $5647.00 | $5647.00 | $5647.00 | 5 |
